Improved survival for patients with de novo metastatic prostate cancer in the last 20 years

详细信息    查看全文

• 作者：Kasper Drimer Berg^a ; ^b ; ^{kasperdrimerberg@gmail.com} ; Frederik Birkebæ ; k Thomsen^a ; ^c ; Marta K. Mikkelsen^c ; Inga J. Ingimarsdó ; ttir^d ; ^e ; Rikke B. Hansen^c ; Anne Mette T. Kejs^e ; Klaus Brasso^a
• 关键词：Prostate cancer ; Metastatic prostate cancer ; Endocrine therapy ; Overall survival ; Cancer-specific survival ; Relative survival
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：72
• 期：Complete
• 页码：20-27
• 全文大小：620 K
• 卷排序：72

文摘

Prostate cancer (PCa)-specific survival has improved over time for men diagnosed with metastatic PCa. Relative survival has increased over time for men diagnosed with metastatic PCa. Only one in four received second-line therapies after failing first-line therapy. Lead-time bias and new effective therapies have led to apparent improved survival.